申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
公开号:US06350763B1
公开(公告)日:2002-02-26
Novel compounds of the formula I
which are useful for treating or preventing inflammatory and immune cell-mediated diseases. Exemplary compounds are:
1-acetyl-5-(R)-(4-bromobenzyl)-3-(2,6-dichloropyridin-4-yl)-5-methylimidazoline-2,4-dione;
5-(R)-(4-bromobenzyl)-3-(2,6-dichloropyridin-4-yl)-1-ethyl-5-methylimidazoline-2,4-dione; and,
5-(R)-(4-bromobenzyl)-3-(2,6-dichloropyridin-4-yl)-5-methylimidazoline-2,4-dione.
化合物I的新颖化合物,适用于治疗或预防炎症和免疫细胞介导的疾病。示例化合物包括:1-乙酰基-5-(R)-(4-溴苯甲基)-3-(2,6-二氯吡啶-4-基)-5-甲基咪唑啉-2,4-二酮;5-(R)-(4-溴苯甲基)-3-(2,6-二氯吡啶-4-基)-1-乙基-5-甲基咪唑啉-2,4-二酮;和5-(R)-(4-溴苯甲基)-3-(2,6-二氯吡啶-4-基)-5-甲基咪唑啉-2,4-二酮。